Innate Cell Engagers (ICE®) to Trigger Innate Immunity to Fight Cancer

Time: 3:30 pm
day: Workshop


– Review pre-clinical and clinical development of Innate Cell Engagers (ICE®), derived from the Redirected Optimized Cell Killing (ROCK®) platform
– Present the current development landscape of ICE® in hematological and solid cancer
– Present recent pre-clinical in vitro and in vivo work demonstrating efficacy and novel insights into the mode-of action of ICE® triggering Antibody-Dependent Cellular Cytotoxicity (ADCC) and Antibody Dependent Cellular Phagocytosis (ADCP)
– Provide preclinical foundation and future perspective to combine ICE® and adoptive cellular NK cell therapy (“in-situ-CAR-NK”) to treat cancer patients